Novo Nordisk’s $2.6 billion bet on a weekly pill in the obesity race

On 29 September 2026, Novo Nordisk agreed to license Hengrui Pharma’s experimental obesity and diabetes drug HRS-1596 for $300 million upfront, up to $2.3 billion in additional milestone payments, and sales royalties.  

The Parties

Novo Nordisk is a Danish drugmaker that develops and sells diabetes and obesity medicines. Its semaglutide brands include Ozempic, for type 2 diabetes, and Wegovy, for weight management.

Hengrui Pharma, formally Jiangsu Hengrui Pharmaceuticals, is a Chinese drugmaker developing medicines for cancer, metabolic, cardiovascular and other diseases. It developed HRS-1596, which targets both GLP-1 and GIP receptors and has potential for once-weekly oral dosing.

Structure & Process

Novo receives rights to develop, manufacture and commercialise HRS-1596 worldwide except mainland China, Hong Kong, Macao and Taiwan.

The Financing Angle

Novo is the payer. The public announcements reviewed identify no deal-specific lenders, debt facility or financing adviser, and do not specify the source of funds.

Payments are staged: $300 million upfront, further payments conditional on development, regulatory and commercial milestones, and royalties on net sales. Much of the potential consideration therefore depends on the drug’s progress and commercial performance.

Why It Matters

The deal adds a potential weekly pill to Novo’s response to Eli Lilly. The “Ozempic fight” spans diabetes and obesity, but the direct obesity-brand contest is Wegovy versus Zepbound.

Lilly has demonstrated an efficacy advantage in injections: in SURMOUNT-5, tirzepatide produced average weight loss of 20.2% versus 13.7% with semaglutide over 72 weeks in adults without diabetes. That comparison used Wegovy doses up to 2.4 mg, not the newer 7.2 mg formulation.

Competition now extends to pills. Novo launched daily oral Wegovy in the US in January 2026; Lilly’s daily oral Foundayo (orforglipron) received FDA approval on 1 April 2026.

The strategic inference: a successful weekly pill could give Novo a convenience advantage over daily tablets while targeting two hormone receptors, as Lilly’s injectable tirzepatide does. However, HRS-1596 is only Phase I-ready: its efficacy and safety remain unproven. The transaction also illustrates how Chinese drug developers can monetise overseas rights while retaining their home-region rights.

Law Firm Contacts

·       Novo — Ropes & Gray: team led by Hannah England and Ian Nilsen, with Katherine Wang and Sabrina Kim.

·       Hengrui — Sidley Austin: team led by Lila Hope, Jennifer Raab and Jiqiang Lin.

·       Hengrui, intellectual-property aspects — Goodwin: team led by Bill Christiansen, Xixi Sun and Yingying Cai.

·       Financial advisers: none identified in the public announcements reviewed.